TY - JOUR
T1 - The European Eye Epidemiology spectral-domain optical coherence tomography classification of macular diseases for epidemiological studies
AU - Gattoussi, Sarra
AU - Buitendijk, Gabrielle H. S.
AU - Peto, Tunde
AU - Leung, Irene
AU - Schmitz-Valckenberg, Steffen
AU - Oishi, Akio
AU - Wolf, Sebastian
AU - Deak, Gabor
AU - Delcourt, Ccile
AU - Klaver, Caroline C. W.
AU - Korobelnik, Jean-Fracnois
AU - Acar, Niyazi
AU - Anas-Tosopoulos, Eleftherios
AU - Azuara-Blanco, Augusto
AU - Berendschot, Tos
AU - Bertelsen, Geir
AU - Binquet, Christine
AU - Bird, Alan
AU - Bobak, Martin
AU - Larsen, Morten Bogelund
AU - Boon, Camiel
AU - Bourne, Rupert
AU - Bretillon, Lionel
AU - Broe, Rebecca
AU - Bron, Alain
AU - Buitendijk, Gabrielle
AU - Cachulo, Maria Luz
AU - Capuano, Vittorio
AU - Carriere, Isabelle
AU - Chakravarthy, Usha
AU - Chan, Michelle
AU - Chang, Petrus
AU - Colijn, Johanna
AU - Cree, Angela
AU - Creuzot-Garcher, Catherine
AU - Cumberland, Phillippa
AU - Cunha-Vaz, Jose
AU - Daien, Vincent
AU - De Jong, Eiko
AU - Deak, Gabor
AU - Delcourt, Cecile
AU - Delyfer, Marie-Noelle
AU - den Hollan-Der, Anneke
AU - Dietzel, Martha
AU - Erke, Maja Gran
AU - Faria, Pedro
AU - Farinha, Claudia
AU - Fauser, Sascha
AU - Finger, Robert
AU - Gorgels, Theo
AU - European Eye Epidemiology (E3) Consortium
N1 - Funding Information:
The E3 consortium thanks Cécile Delcourt, Jean-François Korobelnik, Marie-Bénédicte Rougier and Marie-Noëlle Delyfer for organizing the meetings in Bordeaux in 2011, 2012 and 2013, Stefano Piermarocchi for organizing the meeting in Rome in 2014, Chris Hammond, Paul Foster and Tunde Peto for organizing the meeting in London in 2015. These workshops have received financial support from Carl Zeiss Meditec AG, Laboratoires Théa, Novartis and OOgroup. The sponsors had no role in the design or conduct of this research. Pr. Schmitz-Valckenberg reports grants and personal fees from Allergan, Bayer, Genentech/Roche, Heidelberg Engineering and Novartis/Alcon, personal fees and nonfinancial support from Optos, nonfinancial support from Zeiss MediTec and grants from Formycon, outside the submitted work; Pr. Oishi reports grants from Alcon Japan, Alexander von Humboldt Foundation, Japan Society for the Promotion of Science, Ministry of Health Labour and Welfare, Japan, Takeda Science Foundation and Japan Retinitis Pigmentosa Society, and personal fees from Bayer and Novartis, outside the submitted work; Pr. Wolf reports grants from Allergan, Bayer, and Novartis and nonfinancial support from Heidelberg Engineering and Zeiss, outside the submitted work; Dr. Delcourt reports personal fees from Allergan, Bausch+Lomb, Novartis and Roche and grants and personal fees from Laboratoires Théa, outside the submitted work; Pr. Klaver reports and discloses that an unrestricted grant was obtained from Topcon Europe BV. She is an advisor of Novartis, Bayer and Thea, Capelle aan den IJssel, The Netherlands; Pr. Korobelnik reports personal fees from Alcon, Alimera, Allergan, Bayer, Horus, Novartis, Roche, Thea and Zeiss, outside the submitted work. Other authors have nothing to disclose.
Funding Information:
Cécile Delcourt Inserm U1219 Bordeaux Population Health Reserch Center University of Bordeaux 146 rue Léo Saignat 33076 Bordeaux, Cedex France Tel: +33 557 571 191 Fax: +33 557 571 486 Email: [email protected] The E3 consortium thanks Cécile Delcourt, Jean-Fran©cois Korobelnik, Marie-Bénédicte Rougier and Marie-No€elle Delyfer for organizing the meetings in Bordeaux in 2011, 2012 and 2013, Stefano Pier-marocchi for organizing the meeting in Rome in 2014, Chris Hammond, Paul Foster and Tunde Peto for organizing the meeting in London in 2015. These workshops have received financial support from Carl Zeiss Meditec AG, Laboratoires Théa, Novartis and OOgroup. The sponsors had no role in the design or conduct of this research.Pr. Schmitz-Valckenberg reports grants and personal fees from Allergan, Bayer, Genentech/Roche, Heidelberg Engineering and Novartis/Alcon, personal fees and nonfinancial support from Optos, nonfinancial support from Zeiss MediTec and grants from Formycon, outside the submitted work; Pr. Oishi reports grants from Alcon Japan, Alexander von Humboldt Foundation, Japan Society for the Promotion of Science, Ministry of Health Labour and Welfare, Japan, Takeda Science Foundation and Japan Retinitis Pigmentosa Society, and personal fees from Bayer and Novartis, outside the submitted work; Pr. Wolf reports grants from Allergan, Bayer, and Novartis and nonfinancial support from Heidelberg Engineering and Zeiss, outside the submitted work; Dr. Delcourt reports personal fees from Allergan, Bausch+Lomb, Novar-tis and Roche and grants and personal fees from Laboratoires Théa, outside the submitted work; Pr. Klaver reports and discloses that an unrestricted grant was obtained from Topcon Europe BV. She is an advisor of Novartis, Bayer and Thea, Capelle aan den IJssel, The Netherlands; Pr. Korobelnik reports personal fees from Alcon, Alimera, Allergan, Bayer, Horus, Novartis, Roche, Thea and Zeiss, outside the submitted work. Other authors have nothing to disclose.
Publisher Copyright:
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
PY - 2019/6
Y1 - 2019/6
N2 - Purpose The aim of the European Eye Epidemiology (E3) consortium was to develop a spectral-domain optical coherence tomography (SD-OCT)-based classification for macular diseases to standardize epidemiological studies. Methods A European panel of vitreoretinal disease experts and epidemiologists belonging to the E3 consortium was assembled to define a classification for SD-OCT imaging of the macula. A series of meeting was organized, to develop, test and finalize the classification. First, grading methods used by the different research groups were presented and discussed, and a first version of classification was proposed. This first version was then tested on a set of 50 SD-OCT images in the Bordeaux and Rotterdam centres. Agreements were analysed and discussed with the panel of experts and a final version of the classification was produced. Results Definitions and classifications are proposed for the structure assessment of the vitreomacular interface (visibility of vitreous interface, vitreomacular adhesion, vitreomacular traction, epiretinal membrane, full-thickness macular hole, lamellar macular hole, macular pseudo-hole) and of the retina (retinoschisis, drusen, pigment epithelium detachment, hyper-reflective clumps, retinal pigment epithelium atrophy, intraretinal cystoid spaces, intraretinal tubular changes, subretinal fluid, subretinal material). Classifications according to size and location are defined. Illustrations of each item are provided, as well as the grading form. Conclusion The E3 SD-OCT classification has been developed to harmonize epidemiological studies. This homogenization will allow comparing and sharing data collection between European and international studies.
AB - Purpose The aim of the European Eye Epidemiology (E3) consortium was to develop a spectral-domain optical coherence tomography (SD-OCT)-based classification for macular diseases to standardize epidemiological studies. Methods A European panel of vitreoretinal disease experts and epidemiologists belonging to the E3 consortium was assembled to define a classification for SD-OCT imaging of the macula. A series of meeting was organized, to develop, test and finalize the classification. First, grading methods used by the different research groups were presented and discussed, and a first version of classification was proposed. This first version was then tested on a set of 50 SD-OCT images in the Bordeaux and Rotterdam centres. Agreements were analysed and discussed with the panel of experts and a final version of the classification was produced. Results Definitions and classifications are proposed for the structure assessment of the vitreomacular interface (visibility of vitreous interface, vitreomacular adhesion, vitreomacular traction, epiretinal membrane, full-thickness macular hole, lamellar macular hole, macular pseudo-hole) and of the retina (retinoschisis, drusen, pigment epithelium detachment, hyper-reflective clumps, retinal pigment epithelium atrophy, intraretinal cystoid spaces, intraretinal tubular changes, subretinal fluid, subretinal material). Classifications according to size and location are defined. Illustrations of each item are provided, as well as the grading form. Conclusion The E3 SD-OCT classification has been developed to harmonize epidemiological studies. This homogenization will allow comparing and sharing data collection between European and international studies.
KW - epidemiology
KW - macular degeneration
KW - optical coherence tomography
KW - retina
KW - vitreous
KW - NERVE-FIBER LAYER
KW - AGE-RELATED MACULOPATHY
KW - VITREOMACULAR TRACTION
KW - SD-OCT
KW - THICKNESS
KW - POPULATION
KW - PREVALENCE
KW - SEGMENTATION
KW - DEGENERATION
KW - ABNORMALITIES
U2 - 10.1111/aos.13883
DO - 10.1111/aos.13883
M3 - Article
C2 - 30242982
SN - 1755-375X
VL - 97
SP - 364
EP - 371
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
IS - 4
ER -